“Head and neck cancer is a devastating disease, with even successful treatments causing significant after effects, and yet research into head and neck cancer is relatively less funded than research into other cancers. Team research will be critical to making progress for people with head and neck cancer, and the award of this SPORE in head and neck cancer will make a significant difference in helping us advance treatment options for this difficult-to-treat disease,” said Barbara Burtness, MD, Principal Investigator, Professor of Medicine (Medical Oncology), and Co-Leader, Developmental Therapeutics Research Program at YCC. “The grant will facilitate collaborations between basic, translational, and clinical scientists from our labs and institutions around the country to help identify new curative therapies for our patients.” HNSCC is the seventh most common cancer globally; annually in the United States over 64,000 cases are diagnosed. Current treatments often result in functional impairment, disfigurement, pain, or increased non-cancer mortality, even for patients who are cured, and there are over 13,000 deaths from HNSCC annually. The YHN-SPORE is a collaboration with Fox Chase Cancer Center and the University of North Carolina Lineberger Cancer Center, and is one of three SPOREs awarded to YCC.
“This is very exciting news for YCC and will catapult translational head and neck cancer research at Smilow Cancer Hospital,” said Charles Fuchs, MD, MPH, Director of YCC and Physician-in-Chief at Smilow Cancer Hospital. “This new SPORE represents a highly translational, transdisciplinary team of researchers who will employ deep disease-based expertise to leverage the extraordinary scientific strength of many different departments at our cancer center and with the outstanding resources of cancer centers around the U.S.”
“The investigators participating in our collaborative head and neck cancer SPORE have had significant and far-reaching impact on the field of HNSCC over the past 20 years through paradigm-shifting translational and clinical research,” said Roy S. Herbst, MD, PhD, Chief of Medical Oncology at YCC and Smilow Cancer Hospital and Associate Cancer Center Director for Translational Research at YCC. Over the last decade we have fostered a pilot program focused on building translational research and SPOREs at Yale and it’s wonderful to have seen this team progress and develop under the leadership of Dr. Burtness.”
About Yale Cancer Center and Smilow Cancer Hospital Yale Cancer Center (YCC) is one of only 51 National Cancer Institute-designated comprehensive cancer centers in the nation and the only such center in Connecticut. Cancer treatment for patients is available at Smilow Cancer Hospital through 13 multidisciplinary teams and at 15 Smilow Cancer Hospital Care Centers in Connecticut and Rhode Island. Comprehensive cancer centers play a vital role in the advancement of the NCI’s goal of reducing morbidity and mortality from cancer through scientific research, cancer prevention, and innovative cancer treatment.
# # #